Cerus Corporation to Participate in Upcoming Investor Conferences
Cerus Corporation (NASDAQ:CERS) will participate in two upcoming investor conferences. Cerus' president and CEO, William 'Obi' Greenman, will participate in a fireside chat at The Stifel 2023 Healthcare Conference on November 14th. Cerus' CFO, Kevin Green, will participate in a fireside chat at The Stephens Annual Investment Conference on November 15th.
11/03/2023 - 08:30 AM
CONCORD, Calif. --(BUSINESS WIRE)--
Cerus Corporation (NASDAQ:CERS) announced today that the Company will participate in two upcoming investor conferences:
William “Obi” Greenman, Cerus’ president and chief executive officer, is scheduled to participate in a fireside chat at The Stifel 2023 Healthcare Conference on Tuesday, November 14th , at 4:10 p.m. EST, at the Lotte New York Palace Hotel. A live webcast of the fireside chat will be available here . A replay will be available after the event.
Kevin Green, Cerus’ vice president and chief financial officer, is scheduled to participate in a fireside chat at The Stephens Annual Investment Conference on Wednesday, November 15th , at 1:00 p.m. EST, at the Grand Hyatt in Nashville, TN. A live webcast of the fireside chat will be available here . A replay will be available after the event.
ABOUT CERUS
Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California , the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe , and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231103690847/en/
Jessica Hanover – Vice President, Corporate Affairs
Cerus Corporation
925-288-6137
Source: Cerus Corporation
When will Cerus Corporation participate in the investor conferences?
Cerus Corporation will participate in the investor conferences on November 14th and November 15th.
Who will be representing Cerus Corporation at The Stifel 2023 Healthcare Conference?
William 'Obi' Greenman, Cerus' president and CEO, will be representing the company at The Stifel 2023 Healthcare Conference.
Where will The Stephens Annual Investment Conference take place?
The Stephens Annual Investment Conference will take place at the Grand Hyatt in Nashville, TN.
Will there be a webcast available for the fireside chats?
Yes, there will be a live webcast available for both fireside chats.
Will there be a replay available for the fireside chats?
Yes, a replay will be available after both events.
CERS Rankings
#5035 Ranked by Stock Gains
CERS Stock Data
Industry
Surgical and Medical Instrument Manufacturing
Sector
Manufacturing
Tags
Health Technology, Medical Specialties, Manufacturing, Surgical and Medical Instrument Manufacturing
Country
US
City
Concord
About CERS
cerus corporation is a biomedical products company focused on commercializing the intercept blood system to enhance blood safety. the intercept system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. the nucleic acid targeting mechanism of action enables intercept treatment to inactivate established transfusion threats, such as hepatitis b and c, hiv, west nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. cerus currently markets and sells the intercept blood system for both platelets and plasma in europe, russia, the middle east and selected countries in other regions around the world. the intercept red blood cell system is in clinical development.